Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Deferred Revenue (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Current Deferred Revenue for 3 consecutive years, with $37915.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 55.36% to $37915.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $37915.0, a 55.36% increase, with the full-year FY2024 number at $24404.0, down 26.18% from a year prior.
  • Current Deferred Revenue was $37915.0 for Q3 2025 at bioAffinity Technologies, up from $24404.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $43000.0 in Q2 2023 to a low of $24404.0 in Q3 2024.
  • A 3-year average of $30614.8 and a median of $28154.5 in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: plummeted 39.22% in 2024, then surged 55.36% in 2025.
  • bioAffinity Technologies' Current Deferred Revenue stood at $33058.0 in 2023, then dropped by 26.18% to $24404.0 in 2024, then skyrocketed by 55.36% to $37915.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Current Deferred Revenue are $37915.0 (Q3 2025), $24404.0 (Q2 2025), and $24404.0 (Q1 2025).